Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13405
UPID:
RM49_HUMAN
Alternative names:
39S ribosomal protein L49, mitochondrial; Neighbor of FAU; Protein NOF1
Alternative UPACC:
Q13405; B2R4G6
Background:
The Large ribosomal subunit protein mL49, also known as 39S ribosomal protein L49, mitochondrial, Neighbor of FAU, and Protein NOF1, plays a crucial role in the mitochondrial ribosome. Its primary function is to facilitate protein synthesis within the mitochondria, a process essential for cellular energy production and metabolic functions.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL49 could open doors to potential therapeutic strategies. Its pivotal role in mitochondrial function suggests that insights into its operation could lead to breakthroughs in treating diseases related to mitochondrial dysfunction.